According to recent treatment guidelines for metastatic ccRCC, patients may undergo active surveillance, cytoreductive surgery, or receive a combination of immune checkpoint inhibitors (ICIs) with or without a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI), depending on clinical criteria [101]. This evidence concerns the gene KDR and nonpapillary renal cell carcinoma.